News

Clinipace has closed its acquisition of Worldwide Clinical Research, (WWCR) on October 26th, 2009. With the acquisition, Clinipace has changed its name to Clinipace Worldwide. Reportedly, with specific

Qiagen has signed a definite agreement to acquire SABiosciences, a privately-held developer and manufacturer of disease- and pathway-focused PCR assay panels. The company said that transaction is valued

The Health Canada has accepted for review EpiCept’s New Drug Submission (NDS) for Ceplene (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first

Shire has launched Intuniv (guanfacine) extended release tablets in pharmacies across the US for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.

Daiichi Sankyo has brought a lawsuit before the Intellectual Property High Court to have the decision to nullify a portion of the patent term extension for Levofloxacin Hydrate

Daval International has received Orphan-Drug designation for its anti-inflammatory agent Aimspro for the treatment of amyotrophic lateral sclerosis (ALS) from the FDA. The company said that Aimspro has

As per the agreement, Vertex will utilise Bend’s formulation development and manufacturing services for specific projects and clinical trials, with the goals of both enhancing the delivery of

TNO and Seventh Wave Laboratories (Seventh Wave) have signed a letter of intent with regard to TNO’s in-vitro gastrointestinal models TIM. The letter of intent proposes a collaboration

Enzon Pharmaceuticals has entered into a definitive agreement to sell its specialty pharmaceutical business to the Sigma-Tau Group for $300m plus an additional amount of up to $27m